
On Sunday, Arcus Biosciences Inc. (NYSE:RCUS) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
The ongoing, multi-arm, global Phase 2 EDGE-Gastric study is evaluating the safety and efficacy of various combinations of domvanalimab plus zimberelimab and chemotherapy in this patient population.